NasdaqCM - Nasdaq Real Time Price USD

Organogenesis Holdings Inc. (ORGO)

2.2850 0.0000 (0.00%)
As of 9:38 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
433,140.0000
433,140.0000
450,893.0000
467,359.0000
338,298.0000
Cost of Revenue
106,481.0000
106,481.0000
105,019.0000
114,199.0000
87,319.0000
Gross Profit
326,659.0000
326,659.0000
345,874.0000
353,160.0000
250,979.0000
Operating Expense
314,134.0000
314,134.0000
323,570.0000
280,942.0000
224,279.0000
Operating Income
12,525.0000
12,525.0000
22,304.0000
72,218.0000
26,700.0000
Net Non Operating Interest Income Expense
-2,190.0000
-2,190.0000
-2,009.0000
-7,236.0000
-11,279.0000
Other Income Expense
57.0000
57.0000
-13.0000
-1,896.0000
2,343.0000
Pretax Income
10,392.0000
10,392.0000
20,282.0000
63,086.0000
17,764.0000
Tax Provision
5,447.0000
5,447.0000
4,750.0000
-31,116.0000
530.0000
Net Income Common Stockholders
4,945.0000
4,945.0000
15,532.0000
94,202.0000
17,234.0000
Diluted NI Available to Com Stockholders
4,945.0000
4,945.0000
15,532.0000
94,202.0000
17,234.0000
Basic EPS
0.04
0.04
0.12
0.73
0.16
Diluted EPS
0.04
0.04
0.12
0.70
0.15
Basic Average Shares
131,231.3170
131,231.3170
130,070.2310
128,331.0220
107,737.9360
Diluted Average Shares
132,746.7270
132,746.7270
132,383.1520
133,662.6590
111,360.8310
Total Operating Income as Reported
12,525.0000
12,525.0000
22,304.0000
72,218.0000
26,700.0000
Total Expenses
420,615.0000
420,615.0000
428,589.0000
395,141.0000
311,598.0000
Net Income from Continuing & Discontinued Operation
4,945.0000
4,945.0000
15,532.0000
94,202.0000
17,234.0000
Normalized Income
4,945.0000
4,945.0000
15,532.0000
95,576.5900
15,053.1340
Interest Expense
2,190.0000
2,190.0000
2,009.0000
7,236.0000
11,279.0000
Net Interest Income
-2,190.0000
-2,190.0000
-2,009.0000
-7,236.0000
-11,279.0000
EBIT
12,582.0000
12,582.0000
22,291.0000
70,322.0000
29,043.0000
EBITDA
36,031.0000
36,031.0000
40,322.0000
86,998.0000
37,226.0000
Reconciled Cost of Revenue
106,481.0000
106,481.0000
105,019.0000
114,199.0000
87,319.0000
Reconciled Depreciation
23,449.0000
23,449.0000
18,031.0000
16,676.0000
8,183.0000
Net Income from Continuing Operation Net Minority Interest
4,945.0000
4,945.0000
15,532.0000
94,202.0000
17,234.0000
Total Unusual Items Excluding Goodwill
--
--
--
-1,883.0000
2,246.0000
Total Unusual Items
--
--
--
-1,883.0000
2,246.0000
Normalized EBITDA
36,031.0000
36,031.0000
40,322.0000
88,881.0000
34,980.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0000
Tax Effect of Unusual Items
--
--
--
-508.4100
65.1340
12/31/2020 - 1/5/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EVO Evotec SE
5.04
-1.28%
 
IRWD Ironwood Pharmaceuticals, Inc.
8.12
+0.43%
 
IXHL Incannex Healthcare Inc.
2.2503
-2.16%
 
AGRX Agile Therapeutics, Inc.
0.4000
0.00%
 
LFCR Lifecore Biomedical, Inc.
6.68
+0.60%
 
INCR InterCure Ltd.
2.6449
-0.19%
 
PCRX Pacira BioSciences, Inc.
25.44
-0.24%
 
AQST Aquestive Therapeutics, Inc.
3.9800
+1.27%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.09
-0.63%
 
OPTN OptiNose, Inc.
0.8685
-4.01%